Shandong Xinhua Pharmaceutical Company Limited (00719.HK): LXH-2103 Injection Approved for Clinical Trials

NewTimeSpace News: On June 22, 2026, Xinhua Pharmaceutical (00719.HK) issued an announcement stating that the company recently received the Clinical Trial Approval Notice for LXH-2103 Injection, which was reviewed and issued by the National Medical Products Administration (NMPA). The approval permits the initiation of clinical trials for the treatment of moderate to severe postoperative pain.

According to the announcement, LXH-2103 Injection is a Class 1 innovative chemical drug with a specification of 1ml:50mg. As a novel analgesic, it is designed to address inter-individual variations in efficacy and safety of conventional opioids stemming from CYP2D6 genetic polymorphism.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.